Propranolol in Infantile Hemangioma: A Review Article

Abstract

Hemangioma is the most common benign cutaneous vascular tumor in infants and children. The Hemangioma incidence in the neonates is 2% to 3% that increases to 10% in those younger than one year of age. Before introduction of propranolol in 2008, different medications such as systemic corticosteroids and vincristine, with different side effects, were used for years. Since then, over 200 studies concerning propranolol administration have been published. This study reviews propranolol use in infantile hemangioma.